Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.

Park S, Song CS, Lin CL, Jiang S, Osmulski PA, Wang CM, Marck BT, Matsumoto AM, Morrissey C, Gaczynska ME, Chen Y, Mostaghel EA, Chatterjee B.

Endocrinology. 2020 Jan 2. pii: bqz042. doi: 10.1210/endocr/bqz042. [Epub ahead of print]

PMID:
31894239
2.

Biomarkers and Non-Calcified Coronary Artery Plaque Progression in Older Men Treated with Testosterone.

Shaikh K, Ellenberg SS, Nakanishi R, Snyder PJ, Lee J, Wenger NK, Lewis CE, Swerdloff RS, Preston P, Hamal S, Stephens-Sheilds A, Bhasin S, Cherukuri L, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Matsumoto AM, Molich ME, Alla VM, Birudaraju D, Nezarat N, Rai K, Almeida S, Roy SK, Sheikh M, Trad G, Budoff M.

J Clin Endocrinol Metab. 2019 Nov 30. pii: dgz242. doi: 10.1210/clinem/dgz242. [Epub ahead of print]

PMID:
31784747
3.

Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.

Cunningham GR, Ellenberg SS, Bhasin S, Matsumoto AM, Parsons JK, Preston P, Cauley JA, Gill TM, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Pahor M, Crandall JP, Molitch ME, Cifelli D, Basaria S, Diem SJ, Stephens-Shields AJ, Hou X, Snyder PJ.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):6238-6246. doi: 10.1210/jc.2019-00806.

PMID:
31504596
4.

Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.

Kaipainen A, Zhang A, Gil da Costa RM, Lucas J, Marck B, Matsumoto AM, Morrissey C, True LD, Mostaghel EA, Nelson PS.

Prostate. 2019 Sep;79(13):1530-1542. doi: 10.1002/pros.23874. Epub 2019 Aug 2.

PMID:
31376206
5.

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E.

Eur Urol. 2020 Feb;77(2):144-155. doi: 10.1016/j.eururo.2019.05.042. Epub 2019 Jun 19.

PMID:
31227306
6.

Suboptimal osteoporosis evaluation and treatment in older men with and without additional high-risk factors for fractures.

Narla RR, Hirano LA, Lo SHY, Anawalt BD, Phelan EA, Matsumoto AM.

J Investig Med. 2019 Apr;67(4):743-749. doi: 10.1136/jim-2018-000907. Epub 2019 Feb 5.

PMID:
30723121
7.

Hypothalamic Gliosis by MRI and Visceral Fat Mass Negatively Correlate with Plasma Testosterone Concentrations in Healthy Men.

Berkseth KE, Rubinow KB, Melhorn SJ, Webb MF, Rosalynn B De Leon M, Marck BT, Matsumoto AM, Amory JK, Page ST, Schur EA.

Obesity (Silver Spring). 2018 Dec;26(12):1898-1904. doi: 10.1002/oby.22324.

8.

Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials.

Bhasin S, Ellenberg SS, Storer TW, Basaria S, Pahor M, Stephens-Shields AJ, Cauley JA, Ensrud KE, Farrar JT, Cella D, Matsumoto AM, Cunningham GR, Swerdloff RS, Wang C, Lewis CE, Molitch ME, Barrett-Connor E, Crandall JP, Hou X, Preston P, Cifelli D, Snyder PJ, Gill TM.

Lancet Diabetes Endocrinol. 2018 Nov;6(11):879-890. doi: 10.1016/S2213-8587(18)30171-2.

9.

Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.

Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS.

Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4.

10.

Large divergence in testosterone concentrations between men and women: Frame of reference for elite athletes in sex-specific competition in sports, a narrative review.

Clark RV, Wald JA, Swerdloff RS, Wang C, Wu FCW, Bowers LD, Matsumoto AM.

Clin Endocrinol (Oxf). 2019 Jan;90(1):15-22. doi: 10.1111/cen.13840. Epub 2018 Sep 27. Review. Erratum in: Clin Endocrinol (Oxf). 2019 Sep;91(3):471-473.

PMID:
30136295
11.

Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials.

Wang C, Stephens-Shields AJ, DeRogatis LR, Cunningham GR, Swerdloff RS, Preston P, Cella D, Snyder PJ, Gill TM, Bhasin S, Matsumoto AM, Rosen RC.

J Sex Med. 2018 Jul;15(7):997-1009. doi: 10.1016/j.jsxm.2018.05.008.

12.

Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.

Walsh TJ, Shores MM, Krakauer CA, Forsberg CW, Fox AE, Moore KP, Korpak A, Heckbert SR, Zeliadt SB, Kinsey CE, Thompson ML, Smith NL, Matsumoto AM.

PLoS One. 2018 Jun 22;13(6):e0199194. doi: 10.1371/journal.pone.0199194. eCollection 2018.

13.

Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study.

Rosenberg MA, Shores MM, Matsumoto AM, Bůžková P, Lange LA, Kronmal RA, Heckbert SR, Mukamal KJ.

Clin Cardiol. 2018 Jun;41(6):830-836. doi: 10.1002/clc.22965. Epub 2018 Jun 8.

14.

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA.

J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. doi: 10.1210/jc.2018-00229.

PMID:
29562364
15.

Lessons From the Testosterone Trials.

Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Resnick SM, Budoff M, Mohler ER 3rd, Wenger NK, Cohen HJ, Schrier S, Keaveny TM, Kopperdahl D, Lee D, Cifelli D, Ellenberg SS.

Endocr Rev. 2018 Jun 1;39(3):369-386. doi: 10.1210/er.2017-00234.

16.

The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.

Mohler ER 3rd, Ellenberg SS, Lewis CE, Wenger NK, Budoff MJ, Lewis MR, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Bhasin S, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Pahor M, Preston PE, Hou X, Cifelli D, Snyder PJ.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):681-688. doi: 10.1210/jc.2017-02243. Erratum in: J Clin Endocrinol Metab. 2020 Jan 1;105(1):.

17.

Implementation of a fall screening program in a high risk of fracture population.

Ritchey K, Olney A, Shofer J, Phelan EA, Matsumoto AM.

Arch Osteoporos. 2017 Oct 31;12(1):96. doi: 10.1007/s11657-017-0393-5.

PMID:
29090360
18.

AGING, DIABETES, AND FALLS.

Vinik AI, Camacho P, Reddy S, Valencia WM, Trence D, Matsumoto AM, Morley JE.

Endocr Pract. 2017 Sep;23(9):1117-1139. doi: 10.4158/EP171794.RA. Epub 2017 Jul 13. Review.

PMID:
28704101
19.

SARCOPENIA: AN ENDOCRINE DISORDER?

McKee A, Morley JE, Matsumoto AM, Vinik A.

Endocr Pract. 2017 Sep;23(9):1140-1149. doi: 10.4158/EP171795.RA. Epub 2017 Jul 13. Review.

PMID:
28704095
20.

A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications.

Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R.

Endocr Rev. 2017 Aug 1;38(4):302-324. doi: 10.1210/er.2017-00025. Review.

21.

Cognitive Function After Testosterone Treatment.

Resnick SM, Matsumoto AM, Stephens-Shields AJ.

JAMA. 2017 Jun 13;317(22):2335-2336. doi: 10.1001/jama.2017.5245. No abstract available.

PMID:
28609530
22.

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB.

Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7.

23.

Dose-response effects of sex hormone concentrations on body composition and adipokines in medically castrated healthy men administered graded doses of testosterone gel.

Thirumalai A, Rubinow KB, Cooper LA, Amory JK, Marck BT, Matsumoto AM, Page ST.

Clin Endocrinol (Oxf). 2017 Jul;87(1):59-67. doi: 10.1111/cen.13342. Epub 2017 Apr 26.

24.

A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management.

Grossmann M, Matsumoto AM.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):1067-1075. doi: 10.1210/jc.2016-3580. Review.

25.

Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe.

Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, Lapauw B, Fiers T, Matsumoto AM, Bhasin S.

J Clin Endocrinol Metab. 2017 Apr 1;102(4):1161-1173. doi: 10.1210/jc.2016-2935.

26.

Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.

Resnick SM, Matsumoto AM, Stephens-Shields AJ, Ellenberg SS, Gill TM, Shumaker SA, Pleasants DD, Barrett-Connor E, Bhasin S, Cauley JA, Cella D, Crandall JP, Cunningham GR, Ensrud KE, Farrar JT, Lewis CE, Molitch ME, Pahor M, Swerdloff RS, Cifelli D, Anton S, Basaria S, Diem SJ, Wang C, Hou X, Snyder PJ.

JAMA. 2017 Feb 21;317(7):717-727. doi: 10.1001/jama.2016.21044.

27.

Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.

Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Nakanishi R, Nezarat N, Matsumoto S, Hou X, Basaria S, Diem SJ, Wang C, Cifelli D, Snyder PJ.

JAMA. 2017 Feb 21;317(7):708-716. doi: 10.1001/jama.2016.21043.

28.

Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial.

Roy CN, Snyder PJ, Stephens-Shields AJ, Artz AS, Bhasin S, Cohen HJ, Farrar JT, Gill TM, Zeldow B, Cella D, Barrett-Connor E, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Lewis CE, Matsumoto AM, Molitch ME, Pahor M, Swerdloff RS, Cifelli D, Hou X, Resnick SM, Walston JD, Anton S, Basaria S, Diem SJ, Wang C, Schrier SL, Ellenberg SS.

JAMA Intern Med. 2017 Apr 1;177(4):480-490. doi: 10.1001/jamainternmed.2016.9540.

29.

Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial.

Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM.

JAMA Intern Med. 2017 Apr 1;177(4):471-479. doi: 10.1001/jamainternmed.2016.9539. Erratum in: JAMA Intern Med. 2017 Apr 1;177(4):600. Erratum in: JAMA Intern Med. 2019 Mar 1;179(3):457.

30.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

31.

Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women.

Harrington LB, Marck BT, Wiggins KL, McKnight B, Heckbert SR, Woods NF, LaCroix AZ, Blondon M, Psaty BM, Rosendaal FR, Matsumoto AM, Smith NL.

J Thromb Haemost. 2017 Jan;15(1):80-90. doi: 10.1111/jth.13554. Epub 2017 Jan 8.

32.

Testosterone, Dihydrotestosterone, Sex Hormone-Binding Globulin, and Incident Diabetes Among Older Men: The Cardiovascular Health Study.

Joyce KE, Biggs ML, Djoussé L, Ix JH, Kizer JR, Siscovick DS, Shores MM, Matsumoto AM, Mukamal KJ.

J Clin Endocrinol Metab. 2017 Jan 1;102(1):33-39. doi: 10.1210/jc.2016-2623.

33.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.

34.

Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men.

Chao J, Rubinow KB, Kratz M, Amory JK, Matsumoto AM, Page ST.

J Clin Endocrinol Metab. 2016 Oct;101(10):3724-3731. Epub 2016 Aug 2.

35.

Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels.

Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Bhasin S, Matsumoto AM, Parsons JK, Gill TM, Molitch ME, Farrar JT, Cella D, Barrett-Connor E, Cauley JA, Cifelli D, Crandall JP, Ensrud KE, Gallagher L, Zeldow B, Lewis CE, Pahor M, Swerdloff RS, Hou X, Anton S, Basaria S, Diem SJ, Tabatabaie V, Ellenberg SS, Snyder PJ.

J Clin Endocrinol Metab. 2016 Aug;101(8):3096-104. doi: 10.1210/jc.2016-1645. Epub 2016 Jun 29.

36.

Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.

Thirumalai A, Cooper LA, Rubinow KB, Amory JK, Lin DW, Wright JL, Marck BT, Matsumoto AM, Page ST.

J Clin Endocrinol Metab. 2016 Jul;101(7):2937-44. doi: 10.1210/jc.2016-1483. Epub 2016 May 12.

37.

Effects of Testosterone Treatment in Older Men.

Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS; Testosterone Trials Investigators.

N Engl J Med. 2016 Feb 18;374(7):611-24. doi: 10.1056/NEJMoa1506119.

38.

Doping Status of DHEA Treatment for Female Athletes with Adrenal Insufficiency.

Handelsman DJ, Matsumoto AM, Gerrard DF.

Clin J Sport Med. 2017 Jan;27(1):78-85. doi: 10.1097/JSM.0000000000000300. Review.

PMID:
26844622
39.

Baseline estradiol concentration in community-dwelling Japanese American men is not associated with intra-abdominal fat accumulation over 10 years.

Kocarnik BM, Boyko EJ, Matsumoto AM, Fujimoto WY, Hayashi T, Leonetti DL, Page ST.

Obes Res Clin Pract. 2016 Nov - Dec;10(6):624-632. doi: 10.1016/j.orcp.2015.12.002. Epub 2015 Dec 31.

40.
41.

Testicular fine-needle aspiration for the assessment of intratesticular hormone concentrations.

Lee AP, Roth MY, Nya-Ngatchou JJ, Lin K, Walsh TJ, Page ST, Matsumoto AM, Bremner WJ, Amory JK, Anawalt BD.

Asian J Androl. 2016 Jan-Feb;18(1):21-4. doi: 10.4103/1008-682X.156637.

42.

Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications.

Swerdloff RS, Pak Y, Wang C, Liu PY, Bhasin S, Gill TM, Matsumoto AM, Pahor M, Surampudi P, Snyder PJ.

J Clin Endocrinol Metab. 2015 Sep;100(9):3280-7. doi: 10.1210/JC.2015-1542. Epub 2015 Jun 29.

43.

Recruitment and Screening for the Testosterone Trials.

Cauley JA, Fluharty L, Ellenberg SS, Gill TM, Ensrud KE, Barrett-Connor E, Cifelli D, Cunningham GR, Matsumoto AM, Bhasin S, Pahor M, Farrar JT, Cella D, Rosen RC, Resnick SM, Swerdloff RS, Lewis CE, Molitch ME, Crandall JP, Stephens-Shields AJ, Strorer TW, Wang C, Anton S, Basaria S, Diem S, Tabatabaie V, Dougar D, Hou X, Snyder PJ.

J Gerontol A Biol Sci Med Sci. 2015 Sep;70(9):1105-11. doi: 10.1093/gerona/glv031. Epub 2015 Apr 15.

44.

The association of obesity with sex hormone-binding globulin is stronger than the association with ageing--implications for the interpretation of total testosterone measurements.

Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM.

Clin Endocrinol (Oxf). 2015 Dec;83(6):828-33. doi: 10.1111/cen.12768. Epub 2015 May 11.

45.

External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.

Cho E, Mostaghel EA, Russell KJ, Liao JJ, Konodi MA, Kurland BF, Marck BT, Matsumoto AM, Dalkin BL, Montgomery RB.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):236-43. doi: 10.1016/j.ijrobp.2015.01.020. Epub 2015 Mar 12.

46.

Recent trends in testosterone testing, low testosterone levels, and testosterone treatment among Veterans.

Walsh TJ, Shores MM, Fox AE, Moore KP, Forsberg CW, Kinsey CE, Heckbert SR, Zeliadt S, Thompson ML, Smith NL, Matsumoto AM.

Andrology. 2015 Mar;3(2):287-92. doi: 10.1111/andr.12014. Epub 2015 Feb 13.

47.

Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials.

Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, Bhasin S, Molitch ME, Farrar JT, Cella D, Barrett-Connor E, Cauley JA, Cifelli D, Crandall JP, Ensrud KE, Fluharty L, Gill TM, Lewis CE, Pahor M, Resnick SM, Storer TW, Swerdloff RS, Anton S, Basaria S, Diem S, Tabatabaie V, Hou X, Snyder PJ.

J Clin Endocrinol Metab. 2015 Mar;100(3):1146-55. doi: 10.1210/jc.2014-3818. Epub 2014 Dec 30.

48.

Testosterone treatment of men with mild cognitive impairment and low testosterone levels.

Cherrier MM, Anderson K, Shofer J, Millard S, Matsumoto AM.

Am J Alzheimers Dis Other Demen. 2015 Jun;30(4):421-30. doi: 10.1177/1533317514556874. Epub 2014 Nov 11.

PMID:
25392187
49.

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.

PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014.

50.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

Supplemental Content

Loading ...
Support Center